X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (60) 60
oncology (60) 60
index medicus (46) 46
female (31) 31
aged (30) 30
male (29) 29
chemotherapy (28) 28
middle aged (25) 25
carcinoma, non-small-cell lung - drug therapy (21) 21
lung neoplasms - drug therapy (21) 21
adult (19) 19
cancer (19) 19
carcinoma, non-small-cell lung - pathology (18) 18
care and treatment (18) 18
immunotherapy (18) 18
lung neoplasms - pathology (18) 18
lung cancer (17) 17
neoplasm staging (17) 17
antibodies, monoclonal - therapeutic use (15) 15
lung cancer, non-small cell (15) 15
aged, 80 and over (14) 14
treatment outcome (14) 14
antineoplastic agents - therapeutic use (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
analysis (12) 12
docetaxel (12) 12
metastasis (12) 12
nivolumab (12) 12
trial (12) 12
antibodies, monoclonal - adverse effects (10) 10
article (10) 10
lung neoplasms - therapy (10) 10
open-label (10) 10
respiratory system (10) 10
carcinoma (9) 9
antineoplastic agents - adverse effects (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
bevacizumab (8) 8
cancer therapies (8) 8
cisplatin (8) 8
hematology, oncology and palliative medicine (8) 8
ipilimumab (8) 8
non-small cell lung carcinoma (8) 8
phase-iii trial (8) 8
prognosis (8) 8
research (8) 8
survival (8) 8
survival rate (8) 8
therapy (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antineoplastic agents (7) 7
carcinoma, non-small-cell lung - therapy (7) 7
disease-free survival (7) 7
drug therapy (7) 7
patients (7) 7
pembrolizumab (7) 7
1st-line treatment (6) 6
abridged index medicus (6) 6
cohort studies (6) 6
lung neoplasms - diagnosis (6) 6
multicenter (6) 6
mutation (6) 6
safety (6) 6
solid tumors (6) 6
carboplatin (5) 5
carcinoma, non-small-cell lung - diagnosis (5) 5
chemistry (5) 5
erlotinib (5) 5
gemcitabine (5) 5
human necessities (5) 5
hygiene (5) 5
leukemia (5) 5
medical or veterinary science (5) 5
metallurgy (5) 5
neoplasms - drug therapy (5) 5
non-hodgkins-lymphoma (5) 5
non-small cell lung cancer (5) 5
organic chemistry (5) 5
ovarian cancer (5) 5
peptides (5) 5
preparations for medical, dental, or toilet purposes (5) 5
adenocarcinoma (4) 4
animals (4) 4
anti-cd20 monoclonal-antibody (4) 4
antimitotic agents (4) 4
apoptosis (4) 4
biomarkers (4) 4
blockade (4) 4
carboplatin - administration & dosage (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
cell lung-cancer (4) 4
clinical trials (4) 4
combination (4) 4
disease progression (4) 4
dosage and administration (4) 4
dose-response relationship, drug (4) 4
flow cytometry (4) 4
follow-up studies (4) 4
genetic aspects (4) 4
health aspects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1497 - 1508
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 02/2016, Volume 374, Issue 5, pp. 493 - 494
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 07/2019, Volume 15, Issue 19, pp. 2287 - 2302
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single... 
1ST-LINE TREATMENT | CTLA-4 BLOCKADE | nivolumab | SOLID TUMORS | MAINTENANCE BEVACIZUMAB | PHASE-III | atezolizumab | OPEN-LABEL | DOCETAXEL | STAGE IV | pembrolizumab | ANTI-PD-1 ANTIBODY | ONCOLOGY | tumor mutational burden | immunotherapy | ipilimumab | PD-L1 | CTLA-4 | PD-1 | non-small-cell lung cancer
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 05/2018, Volume 16, Issue 5, pp. 364 - 374
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor... 
Programmed death ligand 1 (PD-L1) | Immune-related adverse events (irAEs) | Programmed death 1 (PD-1) | Immunotherapy
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 09/2018, Volume 14, Issue 9, pp. 529 - 535
Journal Article
Future oncology (London, England), 05/2019
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single... 
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 05/2018, Volume 38, Issue 38, pp. 696 - 707
Although lung cancer remains the leading cause of cancer-related mortality in the United States and worldwide, the rate at which Americans are dying from lung... 
Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - pathology | Carcinoma, Non-Small-Cell Lung - diagnosis | Lung Neoplasms - diagnosis | Humans
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 2512 - 2512
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.